INSYS Therapeutics Appoints Elizabeth Bohlen to Board of Directors
August 09 2018 - 7:00AM
INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the
development, manufacture and commercialization of pharmaceutical
cannabinoids and spray technology, today announced the appointment
of Elizabeth Bohlen as a new independent member of its Board of
Directors.
Ms. Bohlen is the chief operating officer of the Archdiocese of
Chicago, where she oversees the organization’s administrative
functions. She joined the Archdiocese in 2011 after 16 years
at McKinsey & Co., where, as a partner, she provided strategic
counsel to multinational companies across the retail, consumer and
healthcare industries.
“I am delighted that Betsy has joined the Board and brings her
expertise in business strategy and organizational transformation to
INSYS,” said Steven Meyer, chairman of the INSYS Therapeutics Board
of Directors. “We look forward to the benefit of her counsel as we
continue to evolve INSYS into a leader in pharmaceutical
cannabinoids and novel drug delivering systems to address serious
unmet medical needs.”
Prior to assuming her current role in 2015, Ms. Bohlen served in
a variety of other leadership positions at the Archdiocese of
Chicago, including chief financial officer. She began her career as
a financial analyst at The First Boston Corp. (now CSFB) and later
worked at McKinsey as a management consultant from 1995 to 2011.
Her education includes a B.A. in economics from the University of
Notre Dame and an M.B.A. from Harvard Business School.
About INSYS
INSYS Therapeutics is a specialty pharmaceutical company that
develops and commercializes innovative drugs and novel drug
delivery systems of therapeutic molecules that improve patients’
quality of life. Using proprietary spray technology and
capabilities to develop pharmaceutical cannabinoids, INSYS is
developing a pipeline of products intended to address unmet medical
needs and the clinical shortcomings of existing commercial
products. INSYS is committed to developing medications for
potentially treating anaphylaxis, epilepsy, Prader-Willi syndrome,
opioid addiction and overdose, and other disease areas with a
significant unmet need.
Forward-Looking Statements
This news release contains forward-looking statements including
regarding our belief in Ms. Bohlen’s leadership experience. These
forward-looking statements are based on management’s expectations
and assumptions as of the date of this news release; actual results
may differ materially from those in these forward-looking
statements as a result of various factors, many of which are beyond
our control. These factors include, but are not limited to, risk
factors described in our filings with the United States
Securities and Exchange Commission, including those factors
discussed under the caption “Risk Factors” in our Annual Report on
Form 10-K for the year ended Dec. 31, 2017 and subsequent
updates that may occur in our Quarterly Reports on Form 10-Q.
Forward-looking statements speak only as of the date of this news
release, and we undertake no obligation to publicly update or
revise these statements, except as may be required by
law.
CONTACT: |
Corporate
Communications |
Investor
Relations |
|
Joe McGrath |
Jackie Marcus or Chris
Hodges |
|
INSYS Therapeutics |
Alpha IR Group |
|
480-500-3101 |
312-445-2870 |
|
jmcgrath@insysrx.com |
INSY@alpha-ir.com |
|
|
|
INSYS THERAPEUTICS, INC. (NASDAQ:INSY)
Historical Stock Chart
From Mar 2024 to Apr 2024
INSYS THERAPEUTICS, INC. (NASDAQ:INSY)
Historical Stock Chart
From Apr 2023 to Apr 2024